Higher PARP activity has been noted in cancer cells with increased proliferation and chemoradioresistance, and this has led to the development of PARP inhibitors, which reduce the cancer cell's ability to repair single‐ and double‐strand breaks generated by RT and lead to cell death. The gene discussed is PARP1; the disease is cancer.